A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
NCT ID: NCT06855771
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
130 participants
INTERVENTIONAL
2025-09-09
2031-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: BMS-986504 Dose 1
BMS-986504
Specified dose on specified days
Arm B: BMS-986504 Dose 2
BMS-986504
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986504
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).
* At least 1 measurable lesion as per RECIST v1.1.
* Documented radiographic disease progression on or after the most recent line of treatment.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
* Capability to swallow tablets intact (without chewing or crushing).
Exclusion Criteria
* History of gastrointestinal disease or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
* Prior treatment with a PRMT5 or MAT2A inhibitor.
* Known severe hypersensitivity to study treatment and/or any of its excipients.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alaska Oncology and Hematology
Anchorage, Alaska, United States
Local Institution - 0099
Boise, Idaho, United States
Local Institution - 0090
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Local Institution - 0104
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Local Institution - 0079
Shirley, New York, United States
Gabrail Cancer Center
Canton, Ohio, United States
Providence Portland Medical Center
Portland, Oregon, United States
Local Institution - 0103
Portland, Oregon, United States
Local Institution - 0078
Seattle, Washington, United States
Local Institution - 0084
Milwaukee, Wisconsin, United States
GenesisCare - Campbelltown
Campbelltown, New South Wales, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
GenesisCare - St Andrew's
Adelaide, South Australia, Australia
Local Institution - 0039
Beijing, Beijing Municipality, China
Local Institution - 0055
Xiamen, Fujian, China
Local Institution - 0050
Nanning, Guangxi, China
Local Institution - 0043
Nanchang, Jiangxi, China
Local Institution - 0056
Changchun, Jilin, China
Local Institution - 0054
Jinan, Shandong, China
Local Institution - 0044
Linyi, Shandong, China
Local Institution - 0049
Hangzhou, Zhejiang, China
Local Institution - 0053
Linhai, Zhejiang, China
Local Institution - 0045
Marseille, Bouches-du-Rhône, France
Chu Grenoble Alpes
La Tronche, Isère, France
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
Saint-Herblain, Loire-Atlantique, France
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
Hospices Civils de Lyon - Hopital Louis Pradel
Bron, Rhône, France
Hopitaux Universitaires Paris Centre-Hopital Cochin
Paris, , France
Local Institution - 0107
Paris, , France
Hôpital Tenon
Paris, , France
Groupe hospitalier Paris saint Joseph
Paris, Île-de-France Region, France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Bavaria, Germany
Universitätsklinikum Frankfurt Goethe-Universität
Frankfurt am Main, Hesse, Germany
Krankenhaus Martha-Maria Halle-Dölau
Halle, Saxony-Anhalt, Germany
Universitaetsklinikum Koeln
Cologne, , Germany
Universitaetsklinikum Wuerzburg
Würzburg, , Germany
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Napoli, Campania, Italy
Local Institution - 0026
Napoli, Campania, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy
Local Institution - 0022
Milan, Milano, Italy
Local Institution - 0024
Bologna, , Italy
Local Institution - 0019
Milan, , Italy
Local Institution - 0023
Padua, , Italy
Local Institution - 0092
Kashiwa, Chiba, Japan
Local Institution - 0094
Sendai, Miyagi, Japan
Local Institution - 0093
Hirakata, Osaka, Japan
Mazowiecki Szpital Onkologiczny
Wieliszew, Masovian Voivodeship, Poland
Local Institution - 0064
Prabuty, , Poland
Local Institution - 0029
Bucharest, București, Romania
Local Institution - 0036
Florești, Cluj, Romania
Local Institution - 0031
Craiova, Dolj, Romania
Local Institution - 0040
Bucharest, , Romania
Local Institution - 0034
Cluj-Napoca, , Romania
Local Institution - 0030
Iași, , Romania
Local Institution - 0032
Iași, , Romania
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0073
Hospitalet, Barcelona [Barcelona], Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario La Paz
Madrid, Madrid, Comunidad de, Spain
H.R.U Málaga - Hospital General
Málaga, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Karolinska Universitetssjukhuset Solna
Solna, Stockholms Län [se-01], Sweden
Sahlgrenska Universitetssjukhuset
Gothenburg, Västra Götalands Län [se-14], Sweden
Local Institution - 0069
Birmingham, England, United Kingdom
Sarah Cannon Research Institute UK
London, London, City of, United Kingdom
Freeman Hospital
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Study Connect Contact Center www.BMSStudyConnect.com
Role: CONTACT
Phone: 855-907-3286
Email: [email protected]
First line of the email MUST contain NCT # and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Steven Liu, Site 0088
Role: primary
Site 0099
Role: primary
Site 0090
Role: primary
Dipesh Uprety, Site 0100
Role: primary
Site 0104
Role: primary
Kathryn Arbour, Site 0018
Role: primary
Site 0079
Role: primary
Nashat Gabrail, Site 0091
Role: primary
Rachel Sanborn, Site 0098
Role: primary
Site 0103
Role: primary
Site 0078
Role: primary
Site 0084
Role: primary
Jessica Smith, Site 0057
Role: primary
Steven Kao, Site 0059
Role: primary
Wen Xu, Site 0058
Role: primary
VY Broadbridge, Site 0097
Role: primary
Site 0039
Role: primary
Site 0055
Role: primary
Site 0050
Role: primary
Site 0043
Role: primary
Site 0056
Role: primary
Site 0054
Role: primary
Site 0044
Role: primary
Site 0049
Role: primary
Site 0053
Role: primary
Site 0045
Role: primary
Denis Moro-Sibilot, Site 0015
Role: primary
Elvire Pons-Tostivint, Site 0012
Role: primary
Bertrand Mennecier, Site 0095
Role: primary
Michael Duruisseaux, Site 0041
Role: primary
Marie Wislez, Site 0013
Role: primary
Site 0107
Role: primary
Jacques Cadranel, Site 0027
Role: primary
Carole Helissey-Danis, Site 0096
Role: primary
Diego Kauffmann-Guerrero, Site 0068
Role: primary
Fabian Acker, Site 0070
Role: primary
Miriam Moeller, Site 0066
Role: primary
Juergen Wolf, Site 0067
Role: primary
Elisabeth Goebeler, Site 0065
Role: primary
Alessandro Morabito, Site 0020
Role: primary
Site 0026
Role: primary
Diego Cortinovis, Site 0025
Role: primary
Site 0022
Role: primary
Site 0024
Role: primary
Site 0019
Role: primary
Site 0023
Role: primary
Site 0092
Role: primary
Site 0094
Role: primary
Site 0093
Role: primary
Renata Biernacka, Site 0060
Role: primary
Site 0064
Role: primary
Site 0029
Role: primary
Site 0036
Role: primary
Site 0031
Role: primary
Site 0040
Role: primary
Site 0034
Role: primary
Site 0030
Role: primary
Site 0032
Role: primary
Enriqueta Felip Font, Site 0074
Role: primary
Site 0073
Role: primary
Maria Eugenia Olmedo Garcia, Site 0077
Role: primary
Luis Paz-Ares Rodriguez, Site 0071
Role: primary
Javier de Castro Carpeno, Site 0076
Role: primary
Manuel Cobo-Dols, Site 0075
Role: primary
Reyes Bernabe Caro, Site 0089
Role: primary
Oscar Juan Vidal, Site 0072
Role: primary
Luigi DePetris, Site 0002
Role: primary
Andreas Hallqvist, Site 0003
Role: primary
Site 0069
Role: primary
Elisa Fontana, Site 0008
Role: primary
Alastair Greystoke, Site 0004
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-519814-29
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1315-9473
Identifier Type: OTHER
Identifier Source: secondary_id
CA240-0009
Identifier Type: -
Identifier Source: org_study_id